Phase 3 Readout
CRDL: Phase 3 Topline: CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controll
October 21, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 21, 2026
- Company
- Cardiol Therapeutics Inc. (CRDL)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controll
- Indication
- Recurrent Pericarditis